Pheochromocytoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Preoperative treatment of pheochromocytoma is the best way to reduce complications and postoperative follow up is the besy way to reduce recurrence. | |||
==Secondary Prevention<ref name="pmid23642313">{{cite journal| author=Sethi RV, Sethi RK, Herr MW, Deschler DG| title=Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators. | journal=Am J Otolaryngol | year= 2013 | volume= 34 | issue= 5 | pages= 431-8 | pmid=23642313 | doi=10.1016/j.amjoto.2013.03.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23642313 }}</ref>== | |||
* Recurrence is lower than 10% | |||
* Preoperative treatment of pheochromocytoma is the best way to reduce complications and improve morbidity by controlling hypertension during surgery and [[hypotension]] after it. | * Preoperative treatment of pheochromocytoma is the best way to reduce complications and improve morbidity by controlling hypertension during surgery and [[hypotension]] after it. | ||
*All patients with pheochromoctoma need postoperative follow up:<ref name="pmid15644401">{{cite journal| author=Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF| title=Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. | journal=J Clin Endocrinol Metab | year= 2005 | volume= 90 | issue= 4 | pages= 2110-6 | pmid=15644401 | doi=10.1210/jc.2004-1398 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15644401 }}</ref> | *All patients with pheochromoctoma need postoperative follow up:<ref name="pmid15644401">{{cite journal| author=Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF| title=Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. | journal=J Clin Endocrinol Metab | year= 2005 | volume= 90 | issue= 4 | pages= 2110-6 | pmid=15644401 | doi=10.1210/jc.2004-1398 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15644401 }}</ref> | ||
Revision as of 19:18, 10 July 2017
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma secondary prevention |
|
Risk calculators and risk factors for Pheochromocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Preoperative treatment of pheochromocytoma is the best way to reduce complications and postoperative follow up is the besy way to reduce recurrence.
Secondary Prevention[1]
- Recurrence is lower than 10%
- Preoperative treatment of pheochromocytoma is the best way to reduce complications and improve morbidity by controlling hypertension during surgery and hypotension after it.
- All patients with pheochromoctoma need postoperative follow up:[2]
- Genetic testing should be performed in:[2]
- Patients with a family history of pheochromocytoma
- Bilateral or multifocal lesions
- Tumors or malignant or extra-adrenal pheochromocytoma
- Young patients who are aged 50 years or under
References
- ↑ Sethi RV, Sethi RK, Herr MW, Deschler DG (2013). "Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators". Am J Otolaryngol. 34 (5): 431–8. doi:10.1016/j.amjoto.2013.03.010. PMID 23642313.
- ↑ Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF (2005). "Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma". J Clin Endocrinol Metab. 90 (4): 2110–6. doi:10.1210/jc.2004-1398. PMID 15644401.
- ↑ Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004). "Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan". Hypertens Res. 27 (3): 193–202. PMID 15080378.
- ↑ Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004). "Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan". Hypertens Res. 27 (3): 193–202. PMID 15080378.